BR112017013956A2 - proteínas de fusão de citocinas - Google Patents

proteínas de fusão de citocinas

Info

Publication number
BR112017013956A2
BR112017013956A2 BR112017013956-1A BR112017013956A BR112017013956A2 BR 112017013956 A2 BR112017013956 A2 BR 112017013956A2 BR 112017013956 A BR112017013956 A BR 112017013956A BR 112017013956 A2 BR112017013956 A2 BR 112017013956A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
cytokine fusion
nucleic acid
acid molecules
present
Prior art date
Application number
BR112017013956-1A
Other languages
English (en)
Other versions
BR112017013956B8 (pt
BR112017013956B1 (pt
BR112017013956A8 (pt
Inventor
Sahin Ugur
GIESEKE Friederike
Backer Ronald
Kreitter Sebastian
Kontermann Roland
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of BR112017013956A2 publication Critical patent/BR112017013956A2/pt
Publication of BR112017013956A8 publication Critical patent/BR112017013956A8/pt
Publication of BR112017013956B1 publication Critical patent/BR112017013956B1/pt
Publication of BR112017013956B8 publication Critical patent/BR112017013956B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção se refere a proteínas de fusão de citocinas e a moléculas de ácido nucleico que codificam essas proteínas de fusão de citoquinas. a presente invenção se refere ainda a células e organismos não humanos. composições farmacêuticas e kits que compreendem as proteínas de fusão de citoquinas ou as moléculas de ácido nucleico que as codificam, bem como a sua utilização como medicamentos.
BR112017013956A 2015-01-15 2016-01-15 Proteínas de fusão de citocinas BR112017013956B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2015/050682 WO2016112983A1 (en) 2015-01-15 2015-01-15 Cytokine fusion proteins
EPPCT/EP2015/050682 2015-01-15
PCT/EP2016/050773 WO2016113395A1 (en) 2015-01-15 2016-01-15 Cytokine fusion proteins

Publications (4)

Publication Number Publication Date
BR112017013956A2 true BR112017013956A2 (pt) 2018-01-16
BR112017013956A8 BR112017013956A8 (pt) 2019-04-02
BR112017013956B1 BR112017013956B1 (pt) 2024-01-23
BR112017013956B8 BR112017013956B8 (pt) 2024-02-06

Family

ID=52394237

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013956A BR112017013956B8 (pt) 2015-01-15 2016-01-15 Proteínas de fusão de citocinas

Country Status (11)

Country Link
US (2) US10301368B2 (pt)
EP (1) EP3245223B1 (pt)
JP (1) JP6813491B2 (pt)
CN (2) CN113801241A (pt)
AU (1) AU2016207955B2 (pt)
BR (1) BR112017013956B8 (pt)
CA (1) CA2971950A1 (pt)
HK (2) HK1246316A1 (pt)
MX (2) MX2017009153A (pt)
NZ (1) NZ733266A (pt)
WO (2) WO2016112983A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
US20190367579A1 (en) * 2017-02-27 2019-12-05 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins
MA47680A (fr) * 2017-02-28 2020-01-08 Sanofi Sa Arn thérapeutique
AU2018247931B2 (en) 2017-04-06 2022-03-03 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
CA3068841A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
JP2021510076A (ja) * 2018-01-10 2021-04-15 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現する免疫細胞
BR112020024179A2 (pt) 2018-06-01 2021-03-30 Sanofi Terapia de combinação para tratar infecção por vírus da hepatite b
AU2019362902A1 (en) * 2018-10-17 2021-04-29 Albert Einstein College Of Medicine Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc)
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
EP4041410A4 (en) * 2019-10-08 2023-12-06 Fred Hutchinson Cancer Center GENETICALLY MODIFIED TRIMERIC CD70 PROTEINS AND THEIR USES
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US8450460B2 (en) * 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
CN102421913A (zh) * 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
EP2949209A1 (en) * 2012-04-24 2015-12-02 Nordischer Maschinenbau Rud. Baader Gmbh + Co Kg A fish accumulator
AU2014233114B2 (en) * 2013-03-15 2018-03-08 Richard S. Kornbluth Composition comprised of antigen linked to a TNF SuperFamily ligand

Also Published As

Publication number Publication date
HK1246315A1 (zh) 2018-09-07
AU2016207955B2 (en) 2020-05-28
CA2971950A1 (en) 2016-07-21
BR112017013956B8 (pt) 2024-02-06
EP3245223B1 (en) 2020-03-04
EP3245223A1 (en) 2017-11-22
CN107428842B (zh) 2021-10-01
US10301368B2 (en) 2019-05-28
AU2016207955A1 (en) 2017-07-20
US10808019B2 (en) 2020-10-20
MX2021010668A (es) 2021-09-28
BR112017013956B1 (pt) 2024-01-23
CN113801241A (zh) 2021-12-17
JP2018503379A (ja) 2018-02-08
WO2016112983A1 (en) 2016-07-21
BR112017013956A8 (pt) 2019-04-02
JP6813491B2 (ja) 2021-01-13
MX2017009153A (es) 2018-02-01
HK1246316A1 (zh) 2018-09-07
US20190276511A1 (en) 2019-09-12
US20180002392A1 (en) 2018-01-04
WO2016113395A1 (en) 2016-07-21
CN107428842A (zh) 2017-12-01
NZ733266A (en) 2022-04-29

Similar Documents

Publication Publication Date Title
BR112017013956A2 (pt) proteínas de fusão de citocinas
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
CY1123642T1 (el) Αντισωματα enanti-pd-1
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CY1121934T1 (el) Αντισωματα anti-fcrn
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
BR112016015105A2 (pt) Conjugados var2csa-droga
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
PE20160528A1 (es) Anticuerpos
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIONTECH RNA PHARMACEUTICALS GMBH (DE) , UNIVERSIT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNIVERSITAET STUTTGART (DE) ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GGMBH (DE) ; BIONTECH SE (DE)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2016, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2768 DE 23/01/2024, QUANTO AO ITEM (73) ENDERECO DO TITULAR.